A Phase 3 interventional study of Nicotinamide Tablet and Nicotinamide Placebo in Glaucoma, sponsored by Singapore Eye Research Institute. Enrolling by invitation at 2 sites in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.
Sponsored by Singapore Eye Research Institute · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Glaucoma with a site in Singapore — 3 open to participants now, 4 under way, 1 of them phase 3. Glaucoma · Singapore.
Among the 28 studies in Glaucoma with a site in Singapore, this one is the 2nd largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 in phase 3, and was the 26th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →3 of the 28 studies in Glaucoma with a site in Singapore are open now. Recruiting first, the newest first:
Singapore Eye Research Institute · Sites in Singapore
Ages 21+
National University of Singapore · Sites in Singapore
Ages 45–75 · Healthy volunteers
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 7 · Phase 4 3
First in 2005; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 520 is above the median of 61 across 965 interventional studies indexed under Glaucoma.
Median enrollment 68 across the 22 interventional studies, 261 across the 6 observational. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 28 have an industry lead sponsor. The 10 most frequent:
Singapore Eye Research Institute is the lead sponsor of 27 studies on the registry; 12 are open to participants now.
Singapore Eye Research Institute has 7 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Glaucoma with a site in Singapore that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06731582Phase 3Singapore Eye Research InstituteNicotinamide Supplementation in Glaucoma | 2027-07 |
| NCT07364929National University of SingaporeAltered Non-Visual Photoreception in Patients With Glaucoma: Impacts on Sleep, Alertness, Mood, and Cognition | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Glaucoma with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if nicotinamide (NAM, vitamin B3) supplementation can delay glaucoma progression 30% above that achieved with conventional glaucoma treatment using topical medication. The main questions it aims to answer are:
Can NAM supplementation improve the visual function of patients with glaucoma measured by visual field perimetry?
Researchers will compare NAM to a placebo (a look-alike substance that contains no drug) to see if NAM works as an adjuvant in glaucoma treatment.
Participants will:
520 subjects with glaucoma will be enrolled (260 per study arm) from Singapore National Eye Centre and National University Hospital Eye Clinic.
The TAMING Glaucoma Study is designed as a phase 3, randomised, placebo-controlled, double-masked, superiority trial with two parallel groups and a primary endpoint of change in visual field progression over two-three years.
Participants who are currently on NAM will be asked to stop taking the tablets for a month prior to screening visit.
The study duration and your follow-up will be approximately 2-3 years. Recruitment: All participants will be sent an e-consent form via email or provided in hard copy for them to read. Participants will be allowed to ask questions and be given as much time as they require to consider whether they would like to participate. It will be made clear that it will not influence their clinical care in any way whether they agree to participate or not or choose to withdraw from the study at any given time. Written informed consent will be sought from participants prior to screening. Participants will be recruited from public and private ophthalmology clinics at the SNEC and NUH ophthalmology outpatient clinics.Research staff will screen medical records/medical history of patients attending glaucoma clinics to identify potential participants. A study team member will approach eligible patients to explain the study in detail either in person.
Screening visit: At screening, a participant's ophthalmic history will be taken to determine whether they are eligible for the study based on the ophthalmic inclusion and exclusion criteria.
Randomisation: Randomisation will be performed as block randomisation, stratified by glaucoma sub-type and trial site, with a 1:1 allocation.
After baseline testing, participants will be allocated to NAM or placebo in a ratio 1:1 utilising block randomisation stratified by glaucoma subtype and trial site. One or both eligible eyes will be enrolled. Statistical corrections will be used for bilaterally in the final analysis.Web-based randomisation will be conducted through REDCap. Research staff involved in data collection or assessing outcomes, statisticians and participants will remain masked to treatment allocation. A unique code will be allocated to each participant rather than a fixed code for each treatment group such that the unblinding of one individual will not affect the study group as a whole. Participants in the treatment group will take NAM (1.5 g/day - 2 tablets with food) for the remainder of the study.
Blinding: After baseline testing, participants will be allocated to NAM or placebo in a ratio 1:1 utilising block randomisation stratified by glaucoma subtype and trial site. Both eyes will be enrolled. Research staff involved in data collection or assessing outcomes, statisticians and participants will remain masked to treatment allocation. The period of supplementation for both the treatment and placebo group would be for 24 months.
EMERGENCY UNBLINDING: To maintain the overall quality and legitimacy of the clinical trial, code breaks should occur only in exceptional circumstances when knowledge of the actual treatment is absolutely essential for further management of the patient. The Principal Investigator should be made aware of such circumstances.The Investigator is encouraged to maintain the blind wherever possible. The Investigator must report all code breaks (with reason) as they occur on their electronic CRF on REDCap. As unblinding may not necessarily be a reason for study drug discontinuation, the actual allocation should not be disclosed to the participant or other members of the research team.
Test procedures: Refraction, Central cornea thickness, best corrected visual acuity, Blood pressure measurement, Urine Pregnancy test, slit lamp biomicroscopy, intra ocularpressure measurement, visual field testing, Fundus imaging, optical coherence tomography, electroretinography (optional), blood sampling for liver tests - Alanine transaminase / aspartate aminotransferase (ALT/AST) and genetics testing , Patient reported outcome measures (PROMs) Questionaire, Health Economic Evaluation (optional).
Discontinuation / withdrawal: the investigator may withdraw a subject from the study treatment if he is in violation of the protocol, experiences a serious or intolerable adverse event, develops symtopms/ conditions listed in the exclusion criteria during the study, wishes to withdraw from treatment. The investigator will also withdraw allsubjects from the study treatment if the study is terminated. Individuals who discontinue the study treatment will be encouraged to continue in the study and complete the evaluations.They are free to withdraw from the study at any time upon their request or the request of their legally acceptable representative. When a subject withdraws from the study, the reasons for withdrawal will be recorded by the investigator. Whenever possible, all subjects who withdraw from the study prematurely will continue to undergo scheduled visits for study assessments (follow-up). Subjects who fail to return for study assessments will be contacted by the research team in an attempt to have them comply with the protocol, by two documented phone calls and one email. Subjects who withdraw will not be replaced and sample size calculation accounts for 15% attrition. If voluntary withdrawal occurs, the subject will be asked to continue scheduled evaluations, complete an end of study evaluation, and be given appropriate care under medical supervision until the symptoms of any adverse event resolve or the subject's condition becomes stable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients aged ³ 21 years, with definitive, treated POAG, PACG including normal tension glaucoma, PDG, PXFG in one or both eyes.
Exclusion Criteria:
Patients with active liver disease or end stage renal failure.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1.5 grams/day (2 tablets of 750 mg each)
Dietary Supplement: Nicotinamide Tablet
2 tablets
Dietary Supplement: Nicotinamide Placebo
1.5 grams/day
2 tablets
Mean Deviation (MD)
≥ 30% reduction in visual field mean deviation progression measured over 2 years compared to current IOP-lowering treatments alone.
Time frame: 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Jul 2027, 40 months after the start.
Of 33 phase 3 interventional studies under Glaucoma, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 40 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niacinamide
Singapore Eye Research Institute